Anosmia and / or Ageusia and Early Corticosteroid Use
Study Details
Study Description
Brief Summary
Time to recover of Anosmia and / or ageusia and early corticosteroid use
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 4 |
Detailed Description
In a study of dexamethasone kinetics in two groups of 15 patients with community-acquired pneumonia, one group was treated with dexamethasone 6 mg/day by mouth and the other with 4 mg/day intravenously. The apparent volume of distribution was 1 L/kg in both groups, but the half-life after oral administration was approximately 7 hours, and after intravenous administration 9 hours. The bioavailability of oral dexamethasone was 81% (95% CI = 54-121%). However, the biological half-life of dexamethasone is much longer, of the order of 36-54 h compared with 18-36 h for prednisolone.
Time to recover of Anosmia and / or ageusia and early corticosteroid use
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Early CS early use of dexamethasone as early as the laboratory confirmation of inflammation. |
Drug: Early-Dexamethasone
early use of dexamethasone as early as laboratory evidence of high inflammatory markers
Other Names:
|
Active Comparator: Late CS Dexamethasone is to be used lately upon the deterioration of cases |
Drug: Late dexamethazone
Use of dexamethasone on deterioration of the cases with increased severity
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Time to recovery [one to 6 weeks]
Time to recovery from anosmia and / or agusia
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Any case with COVID-19
-
Age more than or equal to 18 years
-
Mild to moderate severity
Exclusion Criteria:
-
Diabetes
-
Any contra-indication for the interventional drug
-
Mentally disabled cases
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Asalam | Maadi | Cairo | Egypt | 11433 |
Sponsors and Collaborators
- ClinAmygate
Investigators
- Study Director: Emad R Issak, MD, Assalam Clinics
Study Documents (Full-Text)
None provided.More Information
Publications
- PR0013